^
BIOMARKER:
PD-L1 underexpression
i
Other names: PD-L1, CD274, HPD-L1, PD-L1, B7H1, PDL1, Programmed death ligand 1, B7-H1, B7-H, PDCD1L1, PDCD1LG1, PDCD1 Ligand 1, B7 homolog 1, CD274 Antigen, Programmed cell death 1 ligand 1, CD274 molecule
Entrez ID:
Related biomarkers:
PD-L1 underexpression
Melanoma
ipilimumab
Sensitive
:
A1
PD-L1 underexpression
Melanoma
nivolumab + ipilimumab
Sensitive
:
A1
PD-L1 underexpression
NSCLC
nivolumab + ipilimumab
Sensitive
:
A2
PD-L1 underexpression
LUAD
nivolumab + ipilimumab
Sensitive
:
A2
PD-L1 underexpression
NSCLC
nivolumab
Resistant
:
B
PD-L1 underexpression
NSCLC
pembrolizumab
Sensitive
:
C2
PD-L1 underexpression
NSCLC
camrelizumab
Sensitive
:
C3
PD-L1 underexpression
NSCLC
Immunotherapy
Sensitive
:
C3
PD-L1 underexpression
NSCLC
ipilimumab + cemiplimab
Sensitive
:
C3
PD-L1 underexpression
Urothelial Cancer
nivolumab + IPI-549
Sensitive
:
C3
PD-L1 underexpression
Mantle Cell Lymphoma
ibrutinib
Resistant
:
C3
PD-L1 underexpression
Triple Negative Breast Cancer
atezolizumab + RG6180
Sensitive
:
C3
PD-L1 underexpression
AML
XmAb14045
Sensitive
:
C3
PD-L1 underexpression
Malignant Pleural Mesothelioma
PD1 inhibitor
Resistant
:
C3
PD-L1 underexpression
SCCHN
cetuximab sarotalocan
Sensitive
:
C3
PD-L1 underexpression
NSCLC
avelumab + VX15
Sensitive
:
C3
PD-L1 underexpression
Gastric Adenocarcinoma
toripalimab + surufatinib
Sensitive
:
C3
PD-L1 underexpression
Esophageal Squamous Cell Carcinoma
toripalimab + surufatinib
Sensitive
:
C3
PD-L1 underexpression
CRC
atezolizumab + RG6180
Sensitive
:
C3
PD-L1 underexpression
Melanoma
atezolizumab + RG6180
Sensitive
:
C3
PD-L1 underexpression
NSCLC
atezolizumab + RG6180
Sensitive
:
C3
PD-L1 underexpression
NSCLC
durvalumab
Resistant
:
C3
PD-L1 underexpression
RCC
PD-L1 inhibitor
Sensitive
:
C3
PD-L1 underexpression
NSCLC
Immunotherapy
Resistant
:
C3
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our